Brief: Suven Life Sciences Announces Delay In Phase 2 Study Of Masupirdine

Suven Life Sciences

09/07/2019 09:17

July 9 (Reuters) - Suven Life Sciences Ltd  SUVP.NS :
    * ANNOUNCES DELAY IN TOPLINE PHASE 2 STUDY DATA OF
MASUPIRDINE
    * UNANTICIPATED DELAY DUE TO TECHNICAL REASONS
    * STUDY OUTCOME RESULTS WILL NOT BE PRESENTED AT AAIC-2019
AS
ORIGINALLY PLANNED

Source text for Eikon:  ID:nBSEb8Lntf 
Further company coverage:  SUVP.NS 

 ((Reuters.Briefs@thomsonreuters.com;))